{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:54:02Z","timestamp":1789912442551,"version":"4.0.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"publisher","award":["PIC3i-2015"],"award-info":[{"award-number":["PIC3i-2015"]}],"id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007391","name":"Association pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["(ANR-10-IDEX-0001-0"],"award-info":[{"award-number":["(ANR-10-IDEX-0001-0"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["SIRIC INCa-DGOS-Inserm_12554"],"award-info":[{"award-number":["SIRIC INCa-DGOS-Inserm_12554"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Humanized immune system (HIS) mouse models, generated by engrafting tumors and hematopoietic cells of human (Hu) origin into immunodeficient host mice, effectively recapitulate key aspects of the crosstalk between human immune cells and tumors. These models represent a valuable tool for the preclinical evaluation of immunotherapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we provide a comprehensive comparison of two widely used HIS models: the Hu-CD34+ model, which engrafts Hu-hematopoietic cells derived from Hu-CD34+ hematopoietic stem cells (HSCs), and the Hu-PBMC model, which utilizes Hu-peripheral blood mononuclear cells (PBMCs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We assess the kinetics, quality and extent of immune cell engraftment, as well as the development of graft-versus-host disease (GVHD). Additionally, we investigate the impact of different immunodeficient host mouse strains on immune cell reconstitution in the Hu-CD34+ model. Both HIS models were engrafted with human tumors derived from either cell lines or patient-derived xenografts (PDX), revealing distinct immune-tumor interactions that influenced antitumor responses. Notably, tumor responses to T-cell-directed therapies, including anti-PD1 antibodies, IL-2-anti-IL-2 antibody complexes, and T-cell engagers, varied across these models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings provide novel insights into the properties and limitations of HIS models, offering a critical resource for optimizing next-generation immuno-oncology strategies and guiding the design of future therapeutic interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1730378","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:34:42Z","timestamp":1775540082000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A comprehensive analysis of humanized mouse models for the study of cancer immunotherapies"],"prefix":"10.3389","volume":"17","author":[{"given":"Philippe","family":"De La Rochere","sequence":"first","affiliation":[{"name":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM) U932, and SIRIC Translational Immunotherapy Team, Translational Research Department, Institut Curie, PSL Research University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Loumagne","sequence":"additional","affiliation":[{"name":"Sanofi Oncology","place":["Vitry Sur Seine, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Rathaux","sequence":"additional","affiliation":[{"name":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM) U932, and SIRIC Translational Immunotherapy Team, Translational Research Department, Institut Curie, PSL Research University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Dubois","sequence":"additional","affiliation":[{"name":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM) U932, and SIRIC Translational Immunotherapy Team, Translational Research Department, Institut Curie, PSL Research University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Denizeau","sequence":"additional","affiliation":[{"name":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM) U932, and SIRIC Translational Immunotherapy Team, Translational Research Department, Institut Curie, PSL Research University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Nemati","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Viel","sequence":"additional","affiliation":[{"name":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM) U932, and SIRIC Translational Immunotherapy Team, Translational Research Department, Institut Curie, PSL Research University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Rocha","sequence":"additional","affiliation":[{"name":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM) U932, and SIRIC Translational Immunotherapy Team, Translational Research Department, Institut Curie, PSL Research University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Slavnic","sequence":"additional","affiliation":[{"name":"IT&M STATS, Groupe IT&M","place":["Neuilly-sur-Seine, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayant","family":"Thatte","sequence":"additional","affiliation":[{"name":"Crown Bioscience Inc.","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Qixiang","family":"Li","sequence":"additional","affiliation":[{"name":"Crown Bioscience Inc.","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Crown Bioscience Inc.","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sedlik","sequence":"additional","affiliation":[{"name":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM) U932, and SIRIC Translational Immunotherapy Team, Translational Research Department, Institut Curie, PSL Research University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Decaudin","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University","place":["Paris, France"]},{"name":"Department of Medical Oncology, Institut Curie","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Azar","sequence":"additional","affiliation":[{"name":"Sanofi Oncology","place":["Vitry Sur Seine, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhvinder","family":"Sidhu","sequence":"additional","affiliation":[{"name":"Sanofi Oncology","place":["Vitry Sur Seine, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Piaggio","sequence":"additional","affiliation":[{"name":"Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM) U932, and SIRIC Translational Immunotherapy Team, Translational Research Department, Institut Curie, PSL Research University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003231","article-title":"Immuno-oncology trends: preclinical models, biomarkers, and clinical development","volume":"10","author":"Franklin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.07.001","article-title":"Humanized mice for the study of immuno-oncology","volume":"39","author":"De La Rochere","year":"2018","journal-title":"Trends Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1196\/annals.1394.002","article-title":"Humanized NOD\/LtSz-scid IL2 receptor common gamma chain knockout mice in diabetes research","volume":"1103","author":"Shultz","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-301507","article-title":"Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor\u2013, granulocyte-macrophage colony-stimulating factor\u2013, and interleukin-3\u2013expressing NOD-SCID IL2R\u03b3null humanized mice","volume":"117","author":"Billerbeck","year":"2011","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203543","article-title":"Establishment of a human allergy model using human IL-3\/GM-CSF-transgenic NOG mice","volume":"191","author":"Ito","year":"2013","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1101398108","article-title":"Functional CD47\/signal regulatory protein alpha (SIRP\u03b1) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo","volume":"108","author":"Legrand","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017004358","article-title":"A functional DC cross talk promotes human ILC homeostasis in humanized mice","volume":"1","author":"Lopez-Lastra","year":"2017","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02082","article-title":"The tumor milieu promotes functional human tumor-resident plasmacytoid dendritic cells in humanized mouse models","volume":"11","author":"Maser","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.761448","article-title":"T cell subsets in graft versus host disease and graft versus tumor","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201800636R","article-title":"Lack of acute xenogeneic graft\u2010versus\u2010host disease, but retention of T\u2010cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression","volume":"33","author":"Brehm","year":"2019","journal-title":"FASEB J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1617528","article-title":"A comprehensive welfare scoring system for graft versus host disease clinical assessment in humanised mouse models used for pharmaceutical research","volume":"16","author":"Nowak","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax2625","article-title":"BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers","volume":"12","author":"Coussy","year":"2020","journal-title":"Sci Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0697","article-title":"IL2\/Anti-IL2 complex combined with CTLA-4, but not PD-1, blockade rescues antitumor NK cell function by regulatory T-cell modulation","volume":"7","author":"Caudana","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00335-019-09796-2","article-title":"Humanized mouse models of immunological diseases and precision medicine","volume":"30","author":"Shultz","year":"2019","journal-title":"Mamm Genome"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00186","article-title":"Posttransplant hemophagocytic lymphohistiocytosis driven by myeloid cytokines and vicious cycles of T-cell and macrophage activation in humanized mice","volume":"10","author":"Yoshihara","year":"2019","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.158","article-title":"AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3","volume":"24","author":"Wunderlich","year":"2010","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2014.10.027","article-title":"Potential limitations of IL-2 administration for the treatment of experimental acute graft-versus-host disease","volume":"162","author":"P\u00e9rol","year":"2014","journal-title":"Immunol Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14116","article-title":"A novel xenogeneic graft-versus-host disease model for investigating the pathological role of human CD4+ or CD8+ T cells using immunodeficient NOG mice","volume":"17","author":"Ito","year":"2017","journal-title":"Am J Transplant"},{"key":"B23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s40364-024-00684-9","article-title":"Pathophysiology and preclinical relevance of experimental graft-versus-host disease in humanized mice","volume":"12","author":"Ehx","year":"2024","journal-title":"biomark Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of T cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1551424","article-title":"Engaging T cells for cleanup","volume":"16","author":"Mungalov","year":"2025","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1518948","article-title":"Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1\/PD-1 targeted immunotherapy","volume":"10","author":"Lin","year":"2018","journal-title":"mAbs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxp050","article-title":"The analysis of the functions of human B and T cells in humanized NOD\/shi-scid\/\u03b3cnull (NOG) mice (hu-HSC NOG mice)","volume":"21","author":"Watanabe","year":"2009","journal-title":"Int Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103322","article-title":"Multi-tumor analysis of cancer-stroma interactomes of patient-derived xenografts unveils the unique homeostatic process in renal cell carcinomas","volume":"24","author":"Sueyoshi","year":"2021","journal-title":"iScience"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00002","article-title":"Patient-derived xenograft models of non-small cell lung cancer and their potential utility in personalized medicine","volume":"7","author":"Morgan","year":"2017","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41523-022-00476-0","article-title":"Immunologically \u201ccold\u201d triple negative breast cancers engraft at a higher rate in patient derived xenografts","volume":"8","author":"Petrosyan","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e14566","article-title":"Anti-PD-(L)1 therapy of non-small cell lung cancer\u2013a summary of clinical trials and current progresses","volume":"9","author":"Mortezaee","year":"2023","journal-title":"Heliyon"},{"key":"B33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 Part 1 trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132099","article-title":"Adjuvant immunotherapy for resectable non-small cell lung cancer: current advances and future perspectives","volume":"17","author":"Ravasin","year":"2025","journal-title":"Cancers"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model","volume":"32","author":"Rongvaux","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B36","article-title":"The efficacy of nivolumab for the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Pan","year":"2017","journal-title":"Int J Clin Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9","article-title":"PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2","volume":"32","author":"Carter","year":"2002","journal-title":"Eur J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00786-z","article-title":"Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model","volume":"8","author":"Jespersen","year":"2017","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2322562","article-title":"A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy","volume":"16","author":"Frey","year":"2024","journal-title":"mAbs"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300040r","article-title":"Simultaneous evaluation of treatment efficacy and toxicity for bispecific T\u2010cell engager therapeutics in a humanized mouse model","volume":"37","author":"Yang","year":"2023","journal-title":"FASEB J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-050520-100526","article-title":"Humanized mouse models to evaluate cancer immunotherapeutics","volume":"5","author":"Guil-Luna","year":"2021","journal-title":"Annu Rev Cancer Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-2301","article-title":"A phase I clinical trial and independent patient-derived xenograft study of combined targeted treatment with dacomitinib and figitumumab in advanced solid tumors","volume":"23","author":"Calvo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.10.011","article-title":"An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer","volume":"156","author":"Gitto","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-3510","article-title":"Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2\u2212\/\u2212IL2R\u03b3null immunodeficient mice","volume":"75","author":"Sanmamed","year":"2015","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.106","article-title":"Human PBMC-transferred murine MHC class I\/II-deficient NOG mice enable long-term evaluation of human immune responses","volume":"15","author":"Yaguchi","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071915","article-title":"Humanized mice are precious tools for preclinical evaluation of CAR T and CAR NK cell therapies","volume":"12","author":"Mhaidly","year":"2020","journal-title":"Cancers"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ame2.12353","article-title":"Progress, implications, and challenges in using humanized immune system mice in CAR\u2010T therapy\u2014application evaluation and improvement","volume":"7","author":"Yue","year":"2024","journal-title":"Anim Models Exp Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1730378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:34:45Z","timestamp":1775540085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1730378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2026.1730378"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1730378","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.09.04.674233","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"article-number":"1730378"}}